Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Pain Pract. 2021 Mar;21(3):316-332. doi: 10.1111/papr.12961. Epub 2020 Nov 13.
Perioperative use of ketamine has been discussed widely in many kinds of surgery. The aim of our study was to evaluate the short-term and long-term benefits and safety of ketamine after breast surgery.
We performed a quantitative systematic review. We included randomized controlled trials that compared intravenous administration of ketamine to a placebo control group, or compared bupivacaine in combination with ketamine to bupivacaine alone in thoracic paravertebral blocks or pectoral blocks among patients undergoing breast surgery. The primary outcome was postoperative pain intensity. Secondary outcomes included cumulative opioid consumption during the 0- to 24-hour postoperative period, the effect on postmastectomy pain syndrome, the effect on postoperative depression, and the adverse events associated with the use of ketamine.
Thirteen randomized controlled trials with 1,182 patients were included for analysis. Compared with placebo, intravenous ketamine was effective in reducing wound pain intensity during the first 6 hours after surgery (weighted mean difference [WMD] -0.83; 95% confidence interval [CI] -1.65, -0.01; P = 0.048) and during the first 24 hours after surgery (WMD -0.65; 95% CI -0.95, -0.35; P < 0.001), and in decreasing opioid consumption (WMD -4.14; 95% CI -8.00, -0.29; P = 0.035) during the first 24 hours after surgery, without increasing the risks for gastrointestinal and central nervous system adverse events. Adding ketamine to bupivacaine in thoracic paravertebral blocks was also effective in reducing postoperative wound pain during the first 6 hours after surgery (WMD -0.59; 95% CI, -1.06, -0.12; P = 0.014) and during the first 24 hours after surgery (WMD -0.90; 95% CI -1.27, -0.53; P < 0.001), and in decreasing opioid consumption (WMD - 4.59; 95% CI -5.76, -3.42; P < 0.001) during the first 24 hours after surgery. Perioperative use of ketamine was associated with improved postoperative depression symptoms (standardized mean difference -0.80; 95% CI - 1.34, -0.27; P = 0.003) and less incidence of postmastectomy pain syndrome (relative risk 0.79; 95% CI 0.63, 0.99; P = 0.043).
Ketamine is an effective and safe multimodal analgesic in patients undergoing breast surgery, administered both intravenously and when added to bupivacaine in paravertebral blocks. In addition, ketamine showed a long-term benefit for preventing postoperative depression and postmastectomy pain syndrome.
在许多类型的手术中,围手术期使用氯胺酮已经被广泛讨论。我们的研究目的是评估氯胺酮在乳房手术后的短期和长期益处和安全性。
我们进行了一项定量系统评价。我们纳入了比较静脉给予氯胺酮与安慰剂对照组,或比较布比卡因联合氯胺酮与单纯布比卡因用于胸段椎旁阻滞或胸肌阻滞的随机对照试验,这些试验纳入了接受乳房手术的患者。主要结局是术后疼痛强度。次要结局包括术后 0-24 小时内累积阿片类药物消耗量、对乳腺癌术后疼痛综合征的影响、对术后抑郁的影响以及与氯胺酮使用相关的不良反应。
纳入了 13 项随机对照试验,共 1182 名患者进行了分析。与安慰剂相比,静脉内氯胺酮在术后 6 小时内(加权均数差[WMD] -0.83;95%置信区间[CI] -1.65,-0.01;P = 0.048)和术后 24 小时内(WMD -0.65;95%CI -0.95,-0.35;P < 0.001)有效降低了伤口疼痛强度,同时在术后 24 小时内减少了阿片类药物的消耗(WMD -4.14;95%CI -8.00,-0.29;P = 0.035),但并未增加胃肠道和中枢神经系统不良反应的风险。在胸段椎旁阻滞中添加氯胺酮至布比卡因也有效降低了术后 6 小时内(WMD -0.59;95%CI,-1.06,-0.12;P = 0.014)和术后 24 小时内(WMD -0.90;95%CI -1.27,-0.53;P < 0.001)的伤口疼痛强度,同时减少了术后 24 小时内阿片类药物的消耗(WMD -4.59;95%CI -5.76,-3.42;P < 0.001)。围手术期使用氯胺酮与术后抑郁症状的改善相关(标准化均数差-0.80;95%CI -1.34,-0.27;P = 0.003),且乳腺癌术后疼痛综合征的发生率较低(相对风险 0.79;95%CI 0.63,0.99;P = 0.043)。
氯胺酮是一种有效且安全的多模式镇痛药物,可用于接受乳房手术的患者,无论是静脉内给药还是与布比卡因联合用于椎旁阻滞。此外,氯胺酮显示出预防术后抑郁和乳腺癌术后疼痛综合征的长期益处。